Webinar: Successful Medical Device Registration in EAEU: New Legislation (Part 1)
The webinar discusses and explains the basic, essential, and theoretical matters of the EAEU system, outlines the new approach to the quality, safety, and efficacy assessments, and compares the EAEU system, current national registrations, and EU Medical Device Regulation (MDR).
This webinar focuses on learning:
1. EAEU Legislation on Medical Device registrations
- Legislation structure and comparisons
- Safety and Performance requirements
- Transition period updates
2. EAEU Registration Dossier
- Dossier structure and new changes
Eurasian system for medical device registration will come into force on January 1st, 2022, and will fully replace all national systems of the EAEU member states.
Registering Your MD In The EAEU?
Make use of our experience to facilitate the approval process. Explore your options in a chat with one of our experts.
Who should attend?
Professionals working in the following fields:
- Regulatory
- R&D
- QA/QC
- Compliance
- Product Development
- Manufacturing
Duration: 50 minutes
Speaker: Mikhail Vinogradov, Regulatory Affairs Project Manager
Mikhail Vinogradov, LLM
Regulatory Affairs Project Manager Biomapas
Other content that might interest you:
Effective IMPD Writing. The Quality Part
Webinar: Effective IMPD Writing. The Quality Part Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is...
Medical Device Registration in Russia. The Essentials
Webinar: Successful Medical Device Registration in Russia. The Essentials The current national system for Medical Device registration in Russia was created from scratch and entered into force in 2013. Most experts agree that this system is complex and puzzling – some...
Expediting access through Reliance Pathways: MENA region
Reliance models are review pathways used by Regulators to expedite the patient access to essential pharmaceutical products and to overcome resource constraints and priorities. Recently, several National Competent Authorities (NCA) in the Middle East North Africa (MENA) region have implemented the Abridged and Verification reviews. These regulatory procedures allow the approvement of needed innovative and/or life-saving drugs.
